Results 241 to 250 of about 885,766 (304)

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

open access: yesESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge   +19 more
wiley   +1 more source

Sudden cardiac death

open access: yesForensic Sciences Research, 2019
Joaquín S. Lucena
doaj   +1 more source

Simultaneous vaccination against influenza and respiratory syncytial virus in high‐risk heart failure patients

open access: yesESC Heart Failure, EarlyView.
In a prospective, randomized study of high‐risk HF patients, simultaneous vaccination against influenza and RSV reduced the risk of the primary composite endpoint (hospitalization for HF, all‐cause death, or infection). The main driver of benefit was a lower incidence of infections.
Jan Biegus   +14 more
wiley   +1 more source

Prediction and prognostic role of left ventricular systolic dysfunction in family screening for dilated cardiomyopathy and non‐dilated left ventricular cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
Aims The prognostic significance of detecting left ventricular (LV) systolic dysfunction during family screening programmes (FSPs) in relatives of probands affected by dilated (DCM) and non‐dilated left ventricular (NDLVC) cardiomyopathies remain unclear.
Eva Del Mestre   +17 more
wiley   +1 more source

Integrated role of cardiac magnetic resonance and genetics in predicting left ventricular reverse remodelling in dilated and non‐dilated cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
An integrated approach including late gadolinium enhancement data and genetics to predict left ventricular reverse remodelling in patients with dilated and non‐dilated left ventricular cardiomyopathy. DSP, desmoplakin; FLNC, filamin C; LMNA, lamin A/C; LVRR, left ventricular reverse remodelling; LGE, late gadolinium enhancement; MVA, major ventricular ...
Martina Setti   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy